FARMINGTON HILLS, Mich., Aug. 19, 2019 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute is the first cancer center in Mich

ATHENS, Ga., Aug. 19, 2019 /PRNewswire/ -- The following is included with permission from The Ties That Bind Us, a new interview series with musicians in recovery, by Steve Wildsmith: Addiction serves as a catalyst for the beautiful musical darkness of Nocturnal Blonde

NEW YORK, Aug. 19, 2019 /PRNewswire/ -- Today Fitz Frames unveiled a customized eyewear app specializing in children's glasses. Led by Founder Heidi Hert

ENGLEWOOD, Colo., Aug. 19, 2019 /PRNewswire/ -- MedChain, Inc., an early stage company building globally compliant healthcare blockchain and decentralized applications (dApps) for electronic medical records (EMRs), announces the filing of its Provisional Patent Application related to methods of securely storing patient medical records utilizing Blockchain technology

ROSEMONT, Ill., Aug. 19, 2019 /PRNewswire/ -- Most of the millions of people with varicose veins don't consider them a medical issue, unless they happen to be painful, achy or inflamed.

RONKONKOMA, N.Y., Aug. 19, 2019 /PRNewswire/ -- The Nature's Bounty Co., a global leader in health and wellness, today announced that Faissal Tahiri has joined the company as President, International, reporting to President and CEO Paul Sturman.

WEST LAFAYETTE, Ind., Aug. 19, 2019 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the detection of lung cancer nodules in lung cancer pat

BOSTON, Aug. 19, 2019 /PRNewswire/ -- IDTechEx, a market intelligence and events company focused on emerging technologies, reports that the market for 3D printed medical devices and pharmaceuticals will be worth $6.1 billion by the year 2029. IDTechEx finds this to be a rapidly growing market with compound annual growth rates of up to 1

CRESSKILL, N.J., Aug. 19, 2019 /PRNewswire/ -- Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial).

BROOKLYN, N.Y., Aug. 19, 2019 /PRNewswire/ -- Conventional hemodialysis technology lacks the ability to remove certain toxins in the blood. As a result of the inefficient clearance, certain toxic molecules accumulate to significantly high levels in the tissues of patients with end- stage renal disease (often 20x-100x higher than in individuals with normal renal function)